SINGLE-AGENT THERAPY FOR LOW RISK GESTATIONAL TROPHOBLASTIC NEOPLASIA(LRGTN):A PRELIMINARY REPORTON A RANDOMIZED CLINICALTRIALTO COMPARE PULSE-METHOTREXATE VERSUS PULSE-DACTINOMYCIN

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

EFTEKHAR Z.; RAHIMI MOGHADAM P.; DEHDAR DARGAHI F.; YARANDI F.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: IRANIAN JOURNAL OF PHARMACOLOGY AND THERAPEUTICS (IJPT) Year:2004 | Volume:3 | Issue:2 Page(s): 41-44

Download Full-Text

View:

313

Download:

100

Cites:

Information Journal Paper

Title

SINGLE-AGENT THERAPY FOR LOW RISK GESTATIONAL TROPHOBLASTIC NEOPLASIA(LRGTN):A PRELIMINARY REPORTON A RANDOMIZED CLINICALTRIALTO COMPARE PULSE-METHOTREXATE VERSUS PULSE-DACTINOMYCIN

Author(s)

EFTEKHAR Z. | RAHIMI MOGHADAM P. | DEHDAR DARGAHI F. | YARANDI F. | Issue Writer Certificate

Keywords

GESTATIONAL TROPHOBLASTIC NEOPLASIA

SINGLE-AGENT CHEMOTHERAPY

METHOTREXATE

DACTINOMYCIN

Abstract

The efficacy of SINGLE-AGENT CHEMOTHERAPY for patients with low risk GESTATIONAL TROPHOBLASTIC NEOPLASIA (LRGTN) with METHOTREXATE or DACTINOMYCIN is well established, but efforts continue to reduce the toxicity, the patients" time and cost of treatment. In a randomized clinical trial, we evaluated and compared the efficacy, toxicity and cost effectiveness of pulse-methotrexate versus pulse-dactinomycin as single-agent therapy in LRGTN. Forty low risk GTN patients were randomly assigned to receive pulse-methotrexate (30 mg/m2weekly intramuscularly) (20 cases) or pulse-dactinomycin (1.25 mg/m2every two weeks intramuscularly) (20 cases). Treatment continued if no major toxicity was encountered and beta human chorionic gonadotropin (l3-hCG) values were lower than 5mlU/m2 in three consecutive weeks. Seventy percent of METHOTREXATE group and 90% of DACTINOMYCIN group responded to treatment (100% remission was achieved with no recurrence in one-year follow-up). The mean time to response was 43 days for METHOTREXATE and 66 days for DACTINOMYCIN group (P-value = 0.001). Patients achieved remission after receiving an average of 8 courses of therapy in METHOTREXATE versus 6 courses in DACTINOMYCIN group (P-value = 0.002). The average cost of treatment per course was about 7 US$ for METHOTREXATE and 62 US$ for DACTINOMYCIN group (P-value < 0.001). There were no cases of major toxicity in METHOTREXATE or DACTINOMYCIN groups. Overall, both METHOTREXATE and DACTINOMYCIN were associated with good remission rate. Based on our results, LRGTN treatment with DACTINOMYCIN is somewhat more effective than that with METHOTREXATE, but METHOTREXATE is more cost-effective for both patients and the health system. As the effectiveness of both pulse-methotrexate and pulse-dactinomycin does not differ significantly, pulsedactinomycin is recommended as first-line treatment.

Cites

No record.

References

Cite

APA: Copy

EFTEKHAR, Z., RAHIMI MOGHADAM, P., DEHDAR DARGAHI, F., & YARANDI, F.. (2004). SINGLE-AGENT THERAPY FOR LOW RISK GESTATIONAL TROPHOBLASTIC NEOPLASIA(LRGTN):A PRELIMINARY REPORTON A RANDOMIZED CLINICALTRIALTO COMPARE PULSE-METHOTREXATE VERSUS PULSE-DACTINOMYCIN. IRANIAN JOURNAL OF PHARMACOLOGY AND THERAPEUTICS (IJPT), 3(2), 41-44. SID. https://sid.ir/paper/297055/en

Vancouver: Copy

EFTEKHAR Z., RAHIMI MOGHADAM P., DEHDAR DARGAHI F., YARANDI F.. SINGLE-AGENT THERAPY FOR LOW RISK GESTATIONAL TROPHOBLASTIC NEOPLASIA(LRGTN):A PRELIMINARY REPORTON A RANDOMIZED CLINICALTRIALTO COMPARE PULSE-METHOTREXATE VERSUS PULSE-DACTINOMYCIN. IRANIAN JOURNAL OF PHARMACOLOGY AND THERAPEUTICS (IJPT)[Internet]. 2004;3(2):41-44. Available from: https://sid.ir/paper/297055/en

IEEE: Copy

Z. EFTEKHAR, P. RAHIMI MOGHADAM, F. DEHDAR DARGAHI, and F. YARANDI, “SINGLE-AGENT THERAPY FOR LOW RISK GESTATIONAL TROPHOBLASTIC NEOPLASIA(LRGTN):A PRELIMINARY REPORTON A RANDOMIZED CLINICALTRIALTO COMPARE PULSE-METHOTREXATE VERSUS PULSE-DACTINOMYCIN,” IRANIAN JOURNAL OF PHARMACOLOGY AND THERAPEUTICS (IJPT), vol. 3, no. 2, pp. 41–44, 2004, [Online]. Available: https://sid.ir/paper/297055/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops